# Deramiocel PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/deramiocel

> The PDUFA target action date for deramiocel, sponsored by CAPRICOR THERAPEUTICS, INC. (CAPR), is November 22, 2026, for rare diseases, today. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the deramiocel PDUFA date?

The PDUFA target action date for deramiocel, sponsored by CAPRICOR THERAPEUTICS, INC. (CAPR), is November 22, 2026, for rare diseases, today. Status: scheduled. Press release filed with the SEC (EX-99): "Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026" Last confirmed November 10, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/deramiocel)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-125150, https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/deramiocel#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | deramiocel |
| Codes | CAP-1002 |
| Sponsor | CAPRICOR THERAPEUTICS, INC. (CAPR) https://sec-api.dev/companies/capr/catalysts |
| Indications | [duchenne muscular dystrophy](https://sec-api.dev/indications/duchenne-muscular-dystrophy), [rare diseases, today](https://sec-api.dev/indications/rare-diseases-today), [cardiomyopathy associated with duchenne muscular dystrophy](https://sec-api.dev/indications/cardiomyopathy-associated-with-duchenne-muscular-dystrophy), cardiomyopathy in patients with dmd, cardiomyopathy in patients with duchenne muscular dystrophy, duchenne muscular dystrophy", dated june 26, 2026, treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD), Muscular Dystrophies |
| Modality | biologic |
| FDA designations | orphan, priority review, rmat |

## Timeline

### late 2024: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015519): "Rolling BLA submission initiated in October 2024 with full submission expected by year-end 2024" https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/capr-20241113xex99d1.htm

### Dec 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-03-26, last confirmed 2025-05-14.
- SEC Form 10-Q (accession 0001558370-25-007770): "We completed the full submission of the BLA in December 2024 and in the first quarter of 2025, we were informed by the FDA, they have accepted for review our BLA seeking full approval for deramiocel as a treatment for patients diagnosed with DMD cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000155837025007770/capr-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003707): "We completed the full submission of the BLA in December 2024 and in the first quarter of 2025, we were informed by the FDA, they have accepted for review our BLA seeking full approval for deramiocel as a treatment for patients diagnosed with DMD cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000155837025003707/capr-20241231x10k.htm

### January 2, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: diagnosed with Duchenne muscular dystrophy.
- First seen 2025-01-02, last confirmed 2025-01-02.
- SEC Form 8-K (accession 0001558370-25-000010): "On January 2, 2025, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that it has completed the submission of its Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000155837025000010/capr-20250102x8k.htm

### March 4, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: rare diseases, today.
- First seen 2025-03-04, last confirmed 2025-05-13.
- SEC Form 8-K (accession 0001558370-25-002097): "On March 4, 2025, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing announced that the U.S. Food and Drug Administration ("FDA") has accepted for review its Biologics License Application ("BLA") seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/capr-20250304x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-002097): "SAN DIEGO, March 4, 2025 -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the U.S. Food and Drug Administration ("FDA") has accepted for review its Biologics License Application ("BLA") seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/capr-20250304xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007574): "In March 2025, the FDA accepted for review Capricor's BLA seeking full approval of deramiocel for the treatment of individuals with DMD-cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm

### March 19, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: Duchenne muscular dystrophy.
- First seen 2025-03-19, last confirmed 2025-03-19.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-003304): "Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy" https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm

### June 18, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05126758 (A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-18 (ACTUAL); Lead Sponsor Capricor Inc.." https://clinicaltrials.gov/study/NCT05126758

### Q3 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-07-11, last confirmed 2025-07-11.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-009186): "The HOPE-3 trial is a randomized, double-blind, placebo-controlled clinical trial of 104 patients, with topline results expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/capr-20250711xex99d1.htm

### July 9, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: cardiomyopathy associated with Duchenne muscular dystrophy.
- First seen 2025-07-11, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "COMPLETE RESPONSE letter dated 07/09/2025 for BL 125842 to Capricor, Inc.." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125842_20250709.pdf%22
- SEC Form 8-K (accession 0001558370-25-009186): "On July 11, 2025, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD)." https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/capr-20250711x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-009186): "SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD)." https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/capr-20250711xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-057221): "In July 2025, the FDA changed course, issuing a Complete Response Letter ("CRL") stating it could not approve the application without additional clinical data—notwithstanding its earlier guidance to the contrary, the absence of deficiencies at mid-cycle review, and more than 50 information requests the FDA had issued and Capricor had answered during the review." https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-025657): "The Company received a Complete Response Letter ("CRL") from the FDA in July 2025." https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-125355): "In July 2025, we received a Complete Response Letter ("CRL") from the FDA stating that the application did not meet the statutory requirement for substantial evidence of effectiveness and requesting additional clinical data." https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-097294): "In July 2025, we received a Complete Response Letter ("CRL") from the FDA stating that the application did not meet the statutory requirement for substantial evidence of effectiveness and requesting additional clinical data." https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-060382): "In July 2025, we received a Complete Response Letter ("CRL") from the FDA stating that the application did not meet the statutory requirement for substantial evidence of effectiveness and requesting additional clinical data." https://www.sec.gov/Archives/edgar/data/1133869/000110465926060382/capr-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-029580): "In July 2025, we received a Complete Response Letter ("CRL") from the FDA stating that the application did not meet the statutory requirement for substantial evidence of effectiveness and requesting additional clinical data." https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm

### Aug 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2025-11-10, last confirmed 2025-11-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109119): "Recent Type A meeting with FDA: In August 2025, Capricor held a Type A meeting with FDA following receipt of a Complete Response Letter (CRL) for its Biologics License Application (BLA) for Deramiocel." https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm

### Aug 2025: trial start

- Status: scheduled. Date confidence: month. Stage: 1.
- First seen 2025-08-11, last confirmed 2025-08-11.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011047): "The Phase 1 clinical trial, conducted and funded by NIAID, was initiated in August 2025, with dosing of the first subject expected imminently." https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm

### August 31, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact. Indication: Duchenne muscular dystrophy.
- First seen 2025-03-04, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007574): "Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025" https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-003304): ""We continue to work diligently towards our August 31, 2025 action date for our deramiocel Biologics License Application, directly engaging with the FDA, preparing for pre-approval licensure inspection and preparing for potential commercial launch with our partner Nippon Shinyaku Co. (U.S. subsidiary: NS Pharma Inc)." https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007574): "The application was granted priority review, with a PDUFA action date set for August 31, 2025." https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-003304): "BLA granted priority review with a Prescription Drug User Fee Act (PDUFA) target action date set for August 31, 2025" https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-003304): "Our BLA has been granted Priority Review by the FDA, with a Prescription Drug User Fee Act (PDUFA) action date set for August 31, 2025." https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm
- SEC Form 8-K (accession 0001558370-25-002097): "Additionally, the FDA granted the BLA Priority Review with a Prescription Drug User Fee Act target action date of August 31, 2025." https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/capr-20250304x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-002097): "--FDA assigns PDUFA target action date of August 31, 2025--" https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/capr-20250304xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-002097): "Additionally, the FDA granted the BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of August 31, 2025 and at this time, the FDA has not identified any potential review issues." https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/capr-20250304xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-057221): "In March 2025, the FDA accepted Capricor's application for review, granted it Priority Review (a designation that shortens the FDA's review timeline for therapies that offer significant advances over existing treatments), and set a target decision PDUFA date of August 31, 2025." https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-057221): "And even though the Distribution Agreement mandates that they be established within ninety days of anticipated BLA approval—a deadline the Distributor did not meet ninety days ahead of the original PDUFA date of August 31, 2025." https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007574): ""We continue to have active dialogue with the FDA as they review our BLA and we remain on track with our PDUFA target action date of August 31, 2025." https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-125355): "The FDA accepted the BLA for review, granted Priority Review, and assigned a PDUFA target action date of August 31, 2025." https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-08-11, last confirmed 2025-11-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109119): "Topline results are expected in the coming weeks (Q4 2025)." https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011047): "These results provide a compelling foundation for our submission, and we are fully prepared to supplement the BLA with HOPE-3 data as needed, with topline results expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011047): "The 12-month treatment period in HOPE-3 was recently completed and topline data are expected to be available in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm
- SEC Form 10-Q (accession 0001558370-25-011084): "We recently completed the 12-month treatment period in HOPE-3 and expect to report topline results in the fourth quarter of 2025, although the study remains blinded at present." https://www.sec.gov/Archives/edgar/data/1133869/000155837025011084/capr-20250630x10q.htm

### Q4 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: cardiomyopathy associated with Duchenne muscular dystrophy.
- First seen 2025-07-11, last confirmed 2025-08-11.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011047): "Capricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidance" https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011047): "These results provide a compelling foundation for our submission, and we are fully prepared to supplement the BLA with HOPE-3 data as needed, with topline results expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-009186): "Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy" https://www.sec.gov/Archives/edgar/data/1133869/000155837025009186/capr-20250711xex99d1.htm

### December 3, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: Duchenne muscular dystrophy.
- First seen 2025-11-10, last confirmed 2025-12-03.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-117947): "SAN DIEGO, Dec. 3, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD)." https://www.sec.gov/Archives/edgar/data/1133869/000110465925117947/capr-20251203xex99d1.htm
- SEC Form 8-K (accession 0001104659-25-117947): "On December 3, 2025, Capricor Therapeutics, Inc. (the "Company") announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial." https://www.sec.gov/Archives/edgar/data/1133869/000110465925117947/capr-20251203x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109119): "Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)" https://www.sec.gov/Archives/edgar/data/1133869/000110465925109119/capr-20251110xex99d1.htm

### March 10, 2026: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-03-10, last confirmed 2026-05-07.
- SEC Form 8-K (accession 0001104659-26-025657): "Press Release, titled "Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA", dated March 10, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-057221): "On March 10, 2026, the FDA established a new PDUFA target action date of" https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507xex99d2.htm
- SEC Form 8-K (accession 0001104659-26-025657): "On March 10, 2026, Capricor Therapeutics, Inc. (the "Company" or "Caprcior") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has lifted the previously issued Complete Response Letter ("CRL") and resumed review of its Biologics License Application ("BLA") seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy ("DMD") cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm

### March 10, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: Duchenne muscular dystrophy.
- First seen 2026-03-10, last confirmed 2026-03-10.
- SEC Form 8-K (accession 0001104659-26-025657): "On March 10, 2026, Capricor Therapeutics, Inc. (the "Company" or "Caprcior") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has lifted the previously issued Complete Response Letter ("CRL") and resumed review of its Biologics License Application ("BLA") seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy ("DMD") cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-025657): "SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration ("FDA") has lifted the previously issued Complete Response Letter and resumed review of its Biologics License Application ("BLA") seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy ("DMD") cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310xex99d1.htm

### June 26, 2026: FDA advisory committee meeting

- Status: scheduled. Date confidence: exact. Indication: Duchenne muscular dystrophy.
- First seen 2026-06-26, last confirmed 2026-06-26.
- SEC Form 8-K (accession 0001104659-26-078327): "On June 26, 2026, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration ("FDA") is planning to convene an Advisory Committee meeting to discuss the Company's Biologics License Application ("BLA") seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy ("DMD")." https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm
- SEC Form 8-K (accession 0001104659-26-078327): "Press Release, titled "Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy", dated June 26, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm

### Jul 2026: NDA/BLA submission

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-08-24, last confirmed 2026-08-24.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-100071): "As part of its ongoing discussions with the FDA following the July 2026 Advisory Committee meeting, Capricor submitted an amendment to the BLA that includes 24-month open-label extension data from its pivotal Phase 3 HOPE-3 study and additional robustness analyses, with a request that the FDA review the existing and new data in support of a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3." https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm

### July 29, 2026: FDA advisory committee meeting

- Status: completed, mixed. Date confidence: exact. Stage: 3. Indication: treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD).
- First seen 2026-06-26, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "On July 29, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125842 from Capricor, Inc. for deramiocel (human allogeneic cardiosphere-derived cells) the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD)." https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated
- Federal Register meeting notice: "On July 29, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125842 from Capricor, Inc. for deramiocel (human allogeneic cardiosphere-derived cells) the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD)." https://www.federalregister.gov/documents/2026/06/29/2026-13096/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public
- SEC Form 10-Q (accession 0001104659-26-097294): "On July 29, 2026, the FDA convened an Advisory Committee to review our BLA for Deramiocel." https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm
- SEC Form 8-K (accession 0001104659-26-078327): "The date for the Advisory Committee meeting is July 29, 2026, and the meeting will be available for live streaming." https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-078327): "-Advisory Committee meeting scheduled for July 29, 2026-" https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-100071): "As part of its ongoing discussions with the FDA following the July 2026 Advisory Committee meeting, Capricor submitted an amendment to the BLA that includes 24-month open-label extension data from its pivotal Phase 3 HOPE-3 study and additional robustness analyses, with a request that the FDA review the existing and new data in support of a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3." https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095908): "FDA Advisory Committee Outcome: On July 29, 2026, the Cellular, Tissue and Gene Therapies Advisory Committee voted 3 in favor and 9 against on whether available evidence provides substantial evidence of effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with DMD." https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm
- SEC Form 8-K (accession 0001104659-26-088667): "On July 29, 2026, the U.S. Food and Drug Administration's ("FDA") Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy ("DMD"), a rare and life-threatening disease for which no approved cardiomyopathy treatment currently exists (3 for, 9 against, 0 abstain)." https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-088667): "SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), a rare and life-threatening disease for which there is no approved treatment for this cardiac complication (3 for, 9 against, 0 abstain)." https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729xex99.htm
- SEC Form 10-Q (accession 0001104659-26-097294): "Advisory Committee Meeting: On July 29, 2026, the Cellular, Tissue and Gene Therapies Advisory Committee voted 3 in favor and 9 against on whether available evidence provides substantial evidence of effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with DMD." https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm
- SEC Form 8-K (accession 0001104659-26-088667): "Press Release, titled "Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel", dated July 30, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729x8k.htm

### August 10, 2026: PDUFA date

- Status: delayed. Date confidence: exact.
- First seen 2026-08-13, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095908): "NS Pharma Dispute: The state court was scheduled to hear Capricor's motion for preliminary injunction on August 10, 2026, ahead of the PDUFA action date." https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-097294): "The state court was scheduled to hear Capricor's motion for preliminary injunction on August 10, 2026, ahead of the current PDUFA action date." https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm

### August 22, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-03-10, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-087891): "--Deramiocel BLA Remains Under Active FDA Review, with PDUFA Target Action Date of August 22, 2026--" https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059380): "Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon" https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-057221): "The U.S. Food and Drug Administration has granted Deramiocel Priority Review, with a target PDUFA action date of August 22, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-057221): "The patients are waiting: The FDA has granted Deramiocel Priority Review, with a target action date of August 22, 2026 (the "PDUFA Date"1" https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-027037): "Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026" https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/capr-20260312xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-125355): "The Company initially estimated the contractual commencement date to be August 22, 2026, the original Prescription Drug User Fee Act ("PDUFA") target action date for Deramiocel." https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-097294): "In measuring the right-of-use asset and lease liability, the Company estimated the contractual commencement date of the ARE Lease to be August 22, 2026, the Prescription Drug User Fee Act ("PDUFA") target action date for Deramiocel, representing management's best estimate of the date on which the FDA approval contingency will be resolved, and the resulting rent commencement date to be August 22, 2027." https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm
- SEC Form 8-K (accession 0001104659-26-088667): "The FDA's Prescription Drug User Fee Act ("PDUFA") target action date for the BLA remains August 22, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-088667): "We remain focused on working with the FDA toward approval ahead of the August 22, 2026, PDUFA target action date."" https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729xex99.htm
- SEC Form 8-K (accession 0001104659-26-078327): "The Company's BLA remains on track for a target action date under the Prescription Drug User Fee Act ("PDUFA") of August 22, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059380): ""With the FDA review of our BLA underway and a PDUFA target action date of August 22, 2026, our highest priority is execution: working closely with the Agency, preparing for potential launch, and continuing to build the capabilities of a commercial-stage company." https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059380): "The FDA accepted the Company's Class 2 resubmission as complete, resuming its full review of the BLA, with a PDUFA target action date of August 22, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm

### August 24, 2026: PDUFA date

- Status: delayed. Date confidence: exact.
- First seen 2026-08-24, last confirmed 2026-08-24.
- SEC Form 8-K (accession 0001104659-26-100071): "Press Release, titled "Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA", dated August 24, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824x8k.htm

### November 22, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3. Indication: rare diseases, today.
- First seen 2026-08-24, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125150): "Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026" https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-100071): "SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), from August 22, 2026 to November 22, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-125355): "Our Biologics License Application ("BLA"), as amended, for Deramiocel for the treatment of DMD is currently under review by the U.S. Food and Drug Administration ("FDA") for potential approval in the United States, with a current Prescription Drug User Fee Act ("PDUFA") target action date of November 22, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-125355): "Our BLA for Deramiocel remains under FDA review, with a PDUFA target action date of November 22, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-100071): "- New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication -" https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-125355): "The FDA also extended the PDUFA target action date to November 22, 2026." https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm

### November 22, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-11-10, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001104659-26-125355): "Following the FDA's extension of the PDUFA target action date to November 22, 2026, the Company updated its estimated contractual and rent commencement dates to November 22, 2026 and November 22, 2027, respectively, and remeasured the lease, resulting in an increase to the lease liability and the ROU asset of approximately $73,000." https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm

## Same indication

- [Vasculan® (ifetroban)](https://sec-api.dev/pdufa/ifetroban) (CPIX)
- [INS1201](https://sec-api.dev/pdufa/ins1201) (INSM)
- [Rinvatercept](https://sec-api.dev/pdufa/rinvatercept) (KROS)
- [Rostudirsen](https://sec-api.dev/pdufa/rostudirsen) (DYN)
- [SGT-003](https://sec-api.dev/pdufa/sgt-003) (SLDB)

Calendar months: [June 2026](https://sec-api.dev/fda-calendar/2026-06), [August 2026](https://sec-api.dev/fda-calendar/2026-08), [November 2026](https://sec-api.dev/fda-calendar/2026-11), [November 2027](https://sec-api.dev/fda-calendar/2027-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/deramiocel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Deramiocel PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/deramiocel

```bibtex
@misc{secapidev_pdufa_deramiocel_20261116,
  title        = {Deramiocel PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/deramiocel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_deramiocel_20261116","title":"Deramiocel PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/deramiocel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
